A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
The purpose of the study was to determine whether treatment with a PI3K inhibitor plus letrozole led to an increase in pathologic clinical response and Objective Response Rate compared to treatment with placebo plus letrozole in patients with Breast cancer.
Inclusion Criteria:
Exclusion Criteria:
Birmingham, Alabama 35294-0006, United States
San Francisco, California 94115, United States
Atlanta, Georgia 30322, United States
Baltimore, Maryland 21231, United States
Durham, North Carolina 27710, United States
San Antonio, Texas 78229, United States
San Antonio, Texas 78229, United States
Hong Kong SAR, Hong Kong
Bunkyo-ku, Tokyo 113-8677, Japan
Koto-ku, Tokyo 135 8550, Japan